1918 completed, 687 recruiting, 524 unknown, 514 terminated. 1537 Phase 2, 1087 Phase 1, 730 Not applicable, 348 Phase 3, 73 Phase 4.
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 60 | 2028-07-01 | 2026-10-28 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC | Not yet recruiting | Bladder Cancer Advocacy Network | 1400 | 2027-03-01 | 2026-10-26 | |
| Hugo™ RAS Urology Post-Market Clinical Study Robotic Assisted Urologic Surgery - Prostatectomy, Cystectomy | Not yet recruiting | Medtronic - MITG | 110 | 2027-02-23 | 2026-10-28 | |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. Hyperthermic intravesical chemotherapy (HIVEC) - Non-muscle Invasive Bladder Cancer (NMIBC) | Not applicable | Not yet recruiting | Eight Medical International BV | 30 | 2027-01-01 | 2026-08-14 |
| VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors Low Intensity Surveillance, High Intensity Surveillance - High-Grade Early-Stage Bladder Cancer | Not applicable | Not yet recruiting | VA Office of Research and Development | 2482 | 2027-01-01 | 2026-02-13 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
Showing 20 of 4353. Sign in to see all of them.
Carcinoma, Renal Cell (1958) · Urinary Bladder Neoplasms (1725) · Kidney Neoplasms (956) · Melanoma (408) · Carcinoma, Non-Small-Cell Lung (398) · Neoplasms (382) · Breast Neoplasms (345) · Carcinoma, Transitional Cell (310) · Prostatic Neoplasms (299) · Ovarian Neoplasms (288) · Non-Muscle Invasive Bladder Neoplasms (284) · Colorectal Neoplasms (282) · Lung Neoplasms (274) · Neoplasm Metastasis (262) · Pancreatic Neoplasms (233)
Female Urogenital Diseases and Pregnancy Complications (4352) · Female Urogenital Diseases (4350) · Male Urogenital Diseases (4349) · Urogenital Diseases (4348) · Neoplasms by Site (4329) · Urologic Diseases (4318) · Urogenital Neoplasms (4303) · Neoplasms (3971) · Neoplasms by Histologic Type (2867) · Neoplasms, Glandular and Epithelial (2692) · Kidney Diseases (2570) · Carcinoma (2527) · Adenocarcinoma (2012) · Urinary Bladder Diseases (1833)
pembrolizumab (228) · Gemcitabine (213) · Nivolumab (191) · Sunitinib (163) · Cisplatin (132) · Sorafenib (100) · Bevacizumab (92) · Magnetic Resonance Spectroscopy (91) · Everolimus (86) · Ipilimumab (84) · cabozantinib (79) · Axitinib (78) · pazopanib (73) · Specimen Handling (71) · Cyclophosphamide (70)
National Cancer Institute (NCI) (231) · M.D. Anderson Cancer Center (100) · Pfizer (92) · Memorial Sloan Kettering Cancer Center (91) · Bristol-Myers Squibb (45) · Merck Sharp & Dohme LLC (42) · Novartis Pharmaceuticals (40) · AstraZeneca (33) · Bayer (33) · Children's Oncology Group (33) · Mansoura University (32) · Hoffmann-La Roche (29) · RenJi Hospital (29) · Eli Lilly and Company (28) · Mayo Clinic (28)
United States (2253) · China (468) · France (420) · Canada (352) · United Kingdom (335) · Italy (326) · Spain (318) · Germany (245) · Australia (232) · South Korea (217) · Netherlands (210) · Belgium (159) · Japan (140) · Poland (137) · Denmark (128)
Eric Jonasch, MD (13) · Giuseppe Procopio, MD (10) · Sumanta K Pal (9) · Robert J. Motzer, MD (8)
PMID 37146227, PMID 31401903, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 37526095, PMID 32499241, PMID 33058158, PMID 33947608, PMID 34125951, PMID 38045238, PMID 38167321, PMID 39462179, PMID 16389183, PMID 19097774, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 27939400, PMID 29562804, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37933882, PMID 41969229, PMID 11001674, PMID 12118019, PMID 17340590, PMID 17409436, PMID 17452976, PMID 19179301, PMID 19556464, PMID 19687335, PMID 19949018, PMID 20850152, PMID 21403127, PMID 21831711, PMID 21917625, PMID 22002018, PMID 22280855, PMID 22430088, PMID 22512481, PMID 22658127, PMID 22877502, PMID 23228299, PMID 23850254, PMID 23982601
2023 (46), 2017 (28), 2016 (27), 2019 (24), 2018 (22), P30CA033572 (21), U10CA180886 (21), U10CA032102 (18), 2014 (17), P30CA043703 (17), 2015 (16), U10CA031946 (14), U10CA098543 (14), 2025 (13), P30CA016672 (13)